Figure 2.
Sub-analyses of efficacy and safety of tirzepatide (TZP) in patients with type 2 diabetes: a randomized, placebo-controlled, and dulaglutide-controlled phase 2 trial [57]. * p < 0.05 change from baseline vs. Dulaglutide. # p < 0.05 change from baseline vs. placebo.